Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease

Current Medical Research and Opinion

Volumn 29, Issue 1, 2013, Pages 23-31

  Viallet, François ^a   Pitel, Séverine ^b   Lancrenon, Sylvie ^c   Blin, Olivier ^d  

^a CENTRE HOSPITALIER DU PAYS D AIX   (France)

^b Qualissima   (France)

^c Sylia Stat ^*  (France)

^d TIMONE HOSPITAL   (France)

Author keywords

Parkinson's disease; Pramipexole; Rasagiline; Safety

Indexed keywords

PRAMIPEXOLE; RASAGILINE;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY; ARTHRALGIA; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMOTIONALITY; FAINTNESS; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MOOD DISORDER; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; ORTHOSTATIC HYPERTENSION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHASE 4 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; SEROTONIN SYNDROME; SIDE EFFECT; SLEEP DISORDER; STOMACH PAIN; TREATMENT DURATION; URTICARIA; VISUAL HALLUCINATION; VOMITING; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION;

AGED; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INDANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; SLEEP DISORDERS; TIME FACTORS;

EID: 84871380763     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.752351     Document Type: Article

References (16)

1. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study. Arch Neurol 2002;59:1937-43
2. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-6
3. Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, non-motor outcomes. Lancet Neurol 2011;10:415-23
4. Lew MF, Hauser RA, Hurtig HI, et al. Long-term efficacy of rasagiline in early Parkinson's disease. Int J Neurosci 2010;120:404-8
5. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-53
6. Grosset KA, Grosset DG. Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life. Mov Disord 2005;20:616-19
7. Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson's disease. Mov Disord 2004;19:513-17
8. Tarrants ML, Denarie MF, Castelli-Haley J, et al. Drug therapies for Parkinson's disease: a database analysis of patient compliance and persistence. Am J Geriatr Pharmacother 2010;8:374-83
9. Le Parc JM, Van Ganse E, Moore N, et al. Comparative tolerability of paracetamol, aspirin and ibuprofen for short-term analgesia in patients with muscu-loskeletal conditions: results in 4291 patients. Clin Rheumatol 2002;21:28-31
10. Azilect (rasagiline) Summary of Product Characteristics. November 2010
11. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-78
12. Chou KL. Adverse events from the treatment of Parkinson's disease. Neurol Clin 2008;26(3 Suppl):S65-83, vi
13. Thornton C, Dore CJ, Elsworth JD, et al. The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man. Psychopharmacology (Berl) 1980;70:163-6
14. Lecht S, Haroutiunian S, Hoffman A, et al. Rasagiline-A novel MAO B inhibitor in Parkinson's disease therapy. Ther Clin Risk Manag 2007;3:467-74
15. Gescheidt T, Bares M. Impulse control disorders in patients with Parkinson's disease. Acta Neurol Belg 2011;111:3-9
16. Lee JY, Kim JM, Kim JW, et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord 2010;16:202-7